Treating sickle cell disease by targeting HbS polymerization

  • William A. Eaton
    Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD; and
  • H. Franklin Bunn
    Brigham and Women’s Hospital, Harvard Medical School, Boston, MA

抄録

<jats:title>Abstract</jats:title><jats:p>Although the root cause of sickle cell disease is the polymerization of hemoglobin S (HbS) to form fibers that make red cells less flexible, most drugs currently being assessed in clinical trials are targeting the downstream sequelae of this primary event. Less attention has been devoted to investigation of the multiple ways in which fiber formation can be inhibited. In this article, we describe the molecular rationale for 5 distinct approaches to inhibiting polymerization and also discuss progress with the few antipolymerization drugs currently in clinical trials.</jats:p>

収録刊行物

  • Blood

    Blood 129 (20), 2719-2726, 2017-05-18

    American Society of Hematology

被引用文献 (1)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ